Comparison of early clinical and optical quality-related outcomes after SMILE using VisuMax 800 versus VisuMax 500 for myopia and low-to-moderate astigmatism in a Chinese population: a single-center retrospective study - Summary - MDSpire
Advertisement
Comparison of early clinical and optical quality-related outcomes after SMILE using VisuMax 800 versus VisuMax 500 for myopia and low-to-moderate astigmatism in a Chinese population: a single-center retrospective study
To compare early clinical outcomes, centration accuracy, and optical quality-related parameters after SMILE performed using the VisuMax 800 and VisuMax 500 platforms in a Chinese population with myopia and low-to-moderate astigmatism.
Approach:
Key Findings:
No significant differences in uncorrected or corrected distance visual acuity, safety index, or efficacy index between groups (p > 0.05).
SMILE Pro group had significantly shorter lenticule creation time (9.47 s vs. 27.43 s, p < 0.01).
Lower absolute Y-axis decentration and total optical zone decentration in the SMILE Pro group (both p < 0.01).
Lower postoperative vertical coma in the SMILE Pro group (p = 0.004).
Lower postoperative residual cylindrical error in the SMILE Pro group (p = 0.048).
Interpretation:
Both VisuMax 500 and VisuMax 800 platforms showed favorable safety and efficacy for correcting myopia and low-to-moderate astigmatism, with the SMILE Pro platform demonstrating improved centration and optical quality metrics.
Limitations:
Retrospective design may introduce selection bias.
Single-center study limits generalizability.
Short follow-up period of 3 months.
Conclusion:
SMILE Pro (VisuMax 800) is associated with improved outcomes compared to conventional SMILE (VisuMax 500), warranting further prospective, multicenter studies with larger sample sizes and longer follow-up.
An extended depth of focus intraocular lens approved by the FDA is designed to improve visual range while maintaining contrast sensitivity in cataract surgery.
